Anti-tumor evaluation of benzaldehyde in the dog and cat.
Fourteen dogs and 11 cats with various malignant tumors were treated daily with benzaldehyde at a dosage rate of 10 mg/kg of body weight, orally, divided into 4 doses. Clinical signs of toxicosis were not observed. A partial response (greater than 50% regression) was observed in animals with an oral squamous cell carcinoma and an oral melanoma. A minimal response (less than 50% regression) was observed in animals with a sweat gland adenocarcinoma and a mast cell sarcoma. One dog with an oral melanoma had stabilization of tumor growth for 8 weeks. Seemingly, benzaldehyde has only minimal anti-tumor activity at the dose studied.
D000818:Animals; D000970:Antineoplastic Agents; D001547:Benzaldehydes / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D005500:Follow-Up Studies; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary*
D000970:Antineoplastic Agents; D001547:Benzaldehydes; C032175:benzaldehyde